 The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Incs NASDAQ: PRTK, Nuzyra omadacycline for infections caused by Nontuberculous Mycobacteria NTM. The orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex MABc, currently in an ongoing Phase 2b study initiated by Paratek. 